Nestlé divests its peanut allergy treatment business
Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company that specialises in the diagnosis and treatment of allergies. The transaction was closed upon signing.
Last year, Nestlé announced it would conduct a strategic review of Palforzia. It will now receive milestone payments and ongoing royalties from Stallergenes Greer.
Greg Behar, CEO of Nestlé Health Science, said Nestlé is confident that Stallergenes Greer will take Palforzia forward, allowing Nestlé Health Science to focus on its strengths and growth drivers.
There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
Australians support egg industry amid biosecurity concerns
According to a recent survey, Australians continue to put their trust in the nation's egg...
Changes to NZ food and labelling export exemptions
From 25 September 2025, new export exemptions will be available for certain foods and dietary...
Oceania dairy set for peak volume in October
With milk production gaining momentum as spring arrives, Rabobank predicts global markets will...
